Role of Nonsteroidal Anti-inflammatory Drug in Treatment of Extra-abdominal Desmoid Tumors

다국어 초록 (Multilingual Abstract)

Background: We retrospectively reviewed the outcomes of patients who had been treated with meloxicam for the extra-abdominal desmoid tumors and evaluated the correlation between clinical outcome and clinic pathological variables.
Methods: Twenty patients treated with meloxicam were followed up every 3 to 6 months. Meloxicam administration was planned at 15 mg/day orally for 6 months.
Results: Of the 20 patients evaluated, according to Response Evaluation Criteria in Solid Tumors criteria, there were five patients with partial response (25.0%), eight with stable disease (40.0%), and seven with tumor progression (35.0%). The cumulative probability of dropping out from our nonsurgical strategy using meloxicam was 35.0% at 1 year and 35.0% at 5 years.
Conclusions: The present study suggests that conservative treatment would be a primary treatment option for this perplexing disease even though we were not able to determine that the use of a cyclooxygenase-2 inhibitor would have an additional influence on the natural course of a desmoid tumor.

참고문헌 (Reference)

1 Briand S, "Wait-and-see policy as a first-line management for extra-abdominal desmoid tumors" 96 (96): 631-638, 2014

2 Leithner A, "Treatment of extra-abdominal desmoid tumors with interferon-alpha with or without tretinoin" 73 (73): 21-25, 2000

3 Klein WA, "The use of indomethacin, sulindac, and tamoxifen for the treatment of desmoid tumors associated with familial polyposis" 60 (60): 2863-2868, 1987

4 Sobolewski C, "The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies" 2010 : 215158-, 2010

5 Baumert BG, "The impact of radiotherapy in the treatment of desmoid tumours: an international survey of 110 patients. A study of the Rare Cancer Network" 2 : 12-, 2007

6 Prentice RL, "The analysis of failure times in the presence of competing risks" 34 (34): 541-554, 1978

7 Waddell WR, "Testolactone, sulindac, warfarin, and vitamin K1 for unresectable desmoid tumors" 161 (161): 416-421, 1991

8 Nishida Y, "Successful treatment with meloxicam, a cyclooxygenase-2 inhibitor, of patients with extra-abdominal desmoid tumors: a pilot study" 28 (28): e107-e109, 2010

9 von Mehren M, "Soft tissue sarcoma, version 2.2012: featured updates to the NCCN guidelines" 10 (10): 951-960, 2012

10 Skapek SX, "Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children's Oncology Group (COG) phase II study" 60 (60): 1108-1112, 2013

11 Mace J, "Response of extraabdominal desmoid tumors to therapy with imatinib mesylate" 95 (95): 2373-2379, 2002

12 Kinzbrunner B, "Remission of rapidly growing desmoid tumors after tamoxifen therapy" 52 (52): 2201-2204, 1983

13 Gouin F, "Rating of tumoral growth in non-operated primary or recurrent extra-abdominal aggressive fibromatosis" 93 (93): 546-554, 2007

14 McCollough WM, "Radiation therapy for aggressive fibromatosis: the experience at the University of Florida" 73 (73): 717-725, 1991

15 Gronchi A, "Quality of surgery and outcome in extra-abdominal aggressive fibromatosis: a series of patients surgically treated at a single institution" 21 (21): 1390-1397, 2003

16 Salas S, "Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation" 29 (29): 3553-3558, 2011

17 Barbier O, "Primary or recurring extra-abdominal desmoid fibromatosis: assessment of treatment by observation only" 96 (96): 884-889, 2010

18 Therasse P, "New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada" 92 (92): 205-216, 2000

19 Weiss AJ, "Low-dose chemotherapy of desmoid tumors" 64 (64): 1192-1194, 1989

20 Fernberg JO, "Interferon-induced remission in aggressive fibromatosis of the lower extremity" 38 (38): 971-972, 1999

21 Waddell WR, "Indomethacin and ascorbate inhibit desmoid tumors" 15 (15): 85-90, 1980

22 Bonvalot S, "Extra-abdominal primary fibromatosis: aggressive management could be avoided in a subgroup of patients" 34 (34): 462-468, 2008

23 Francis WP, "Desmoids: a revelation in biology and treatment" 16 (16): 1650-1654, 2009

24 Fiore M, "Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment" 16 (16): 2587-2593, 2009

25 Sherman NE, "Desmoid tumors: a 20-year radiotherapy experience" 19 (19): 37-40, 1990

26 Poon R, "Cyclooxygenase-two (COX-2) modulates proliferation in aggressive fibromatosis (desmoid tumor)" 20 (20): 451-460, 2001

27 Patel SR, "Combination chemotherapy in adult desmoid tumors" 72 (72): 3244-3247, 1993

28 Heinrich MC, "Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor)" 24 (24): 1195-1203, 2006

29 Dominguez-Malagon HR, "Clinical and cellular effects of colchicine in fibromatosis" 69 (69): 2478-2483, 1992

30 Sportiello DJ, "A recurrent pelvic desmoid tumor successfully treated with tamoxifen" 67 (67): 1443-1446, 1991